NEI Research News

Using a canine model of the vision disorder Leber congenital amaurosis, Penn researchers found that photoreceptor cells continue to deteriorate after treatment if it is given too late.

Researchers at the University of California, Berkeley, find that restoring opsins with gene therapy can make 'blind' cells light-sensitive; potential human treatment within three years.

Vision researcher, T. Michael Redmond, Ph.D., chief of the National Eye Institute (NEI) Laboratory of Retinal Cell and Molecular Biology, is a recipient of the 2018 António Champalimaud Vision Award for foundational science discoveries about the molecular

Scientists funded by the National Eye Institute (NEI) report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP).

Silencing a gene called Nrl in mice prevents the loss of cells from degenerative diseases of the retina, according to a new study. The findings could lead to novel therapies for preventing vision loss from human diseases such as retinitis pigmentosa.

In mice genetically predisposed to glaucoma, vitamin B3 added to drinking water is effective at preventing the disease.

Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition.

A new technique that has the potential to treat inherited diseases by removing genetic defects has been shown for the first time to hinder retinitis pigmentosa, a degenerative eye disease with no known cure that can lead to blindness.

Johns Hopkins researchers have developed a method to efficiently turn human stem cells into retinal ganglion cells, the type of nerve cells located within the retina that transmit visual signals from the eye to the brain.

Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health.